시장보고서

상품코드

1736511

에볼라 바이러스 백신 시장 : 바이러스 변종, 유통 채널, 최종 사용자, 지역별(2026-2032년)

Ebola Virus Vaccine Market By Virus Strain, Distribution Channel, End User, & Region for 2026-2032

발행일: 2025년 05월 | 리서치사:

Verified Market Research | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

에볼라 바이러스 백신 시장 평가(2026-2032년)

에볼라 바이러스 백신의 세계 유행 증가가 시장 성장을 가속해 에볼라 바이러스 백신 시장은 2024년에는 1,143만 달러로 평가되었고, 2032년에는 CAGR 32.80%를 나타내 9,176만 달러로 성장할 것으로 예측되고 있습니다.

성장 궤도는 시장 역학의 상승 추세를 보여줍니다. 예측되는 확장은 예측되는 기간의 강력한 성장률을 가리키고 있습니다.

에볼라 바이러스 백신 시장 정의/개요

일반적으로 에볼라 출혈열로 알려진 에볼라는 에볼라 바이러스 속에 속하는 치사성 바이러스 질환 중 하나입니다.

에볼라 출혈열은 혈액 응고로 인한 세계에서 가장 치명적인 질병 중 하나입니다. 가장 전형적으로는 아프리카 국가에서 발생합니다.

에볼라 바이러스병(EVD)은 에볼라 바이러스에 의해 유발되는 인간의 중증으로 치사율이 높은 질병입니다.

에볼라 바이러스 백신 시장은 에볼라 출혈열의 미래 유행을 예방하고 통제하기 위한 세계 이니셔티브의 중요한 부분입니다. 정부, 제약기업, 학술기관, 비영리단체의 협력으로 에볼라 바이러스 백신의 개발, 제조능력, 세계 유통이 추진되고 있습니다. 시장 과제로는 특히 저소득국가에서의 백신의 가격과 입수 용이성 확보, 백신접종의 주저나 가짜 정보에 대한 대처, 장기적인 제조·공급 네트워크의 유지 등을 들 수 있습니다.

세계의 에볼라 바이러스 백신 시장이란?

국립의료도서관에 따르면, 에볼라 출혈열의 발생은 1976년입니다. 수단 남부와 콩고 민주공화국 북부를 습격했고, 6월부터 9월까지 약 4개월간 지속되었으며, 사망률은 각각 53%와 88.1%였습니다. 나중에 확인되고 첫 유행의 책임을 묻는 두 바이러스는 수단 에볼라 바이러스와 자일 에볼라 바이러스였습니다.

에볼라 바이러스 백신 시장의 성장과 개척. 가장 중요한 요구 사항은 에볼라 출혈열의 유행으로 인한 공중 보건 위기에 대처하는 것입니다. 에볼라 바이러스병(EVD)이 인체에 미치는 파괴적인 영향이나 광범위하게 감염될 가능성으로부터 효과적인 예방 대책의 필요성이 부각되고 있습니다.

에볼라 바이러스 백신 시장의 확대·개척은 에볼라 바이러스 백신이 세계보건안전에 대처하는 데 필수적인 요소임을 확립합니다. 과학적, 재정적, 규제적, 지정학적 힘의 조합이 강력한 추진력이 되고 있습니다.

에볼라 바이러스 백신 시장이 직면하는 과제란?

현재의 에볼라 백신에 대한 수요는 대부분이 아웃 브레이크에 대한 대응에 쫓기고 있습니다. 아웃브레이크의 예기치 않은 성질이나 의료자원이 한정되어 있는 중저소득국가에 질병이 집중되어 있는 등의 변수가 있기 때문에 백신접종 프로그램이 널리 실시되기에는 이르지 못했습니다.

예방접종의 개발·제조에는 다액의 비용이 듭니다.그 결과, 백신의 가격 설정이 높아져, 자원이 부족해, 전염병이 가장 유행하기 쉬운 지역에서의 이용 가능성이나 이용의 용이함이 제한될 가능성이 있습니다.

물류의 과제는 인프라가 적은 원격지에서 백신을 배포하고 보관하는 것을 포함합니다.

에볼라 바이러스 백신에 대한 엄격한 규제 허가는 시장 확대를 크게 저해할 수 있습니다. 제한될 수 있습니다.경영자원이 제한된 소규모 기업은 종합적인 임상 검사, 안전성 평가, 제조 요건 등을 요구하는 엄격한 법률에 대한 대응을 고민할 수 있습니다.

Ebola is one of the world's most deadly diseases caused by blood coagulation. It most typically occurs in African countries. It is characterized as a haemorrhagic fever virus because of the coagulation issues that lead to internal bleeding when blood pours from small blood vessels in the body. It is caused by an infection with viruses from the Ebolavirus genus.

Ebola virus disease (EVD) is a serious and frequently fatal sickness in humans caused by the Ebola virus. The market for Ebola vaccines has grown significantly, particularly after the serious Ebola outbreak in West Africa from 2014 to 2016, which emphasized the critical need for effective vaccines to manage outbreaks and protect populations.

The Ebola virus vaccine market is an important part of global efforts to prevent and control future outbreaks of the illness. Collaborations among governments, pharmaceutical corporations, academic institutions, and non-profit groups are driving Ebola virus vaccine development, manufacturing capacity and global distribution. Market challenges include assuring vaccine price and accessibility, particularly in low-income countries, tackling vaccination hesitancy and disinformation, and maintaining long-term manufacturing and supply networks.

What was the global Outbreaks of Ebola Virus Vaccine Market?

According to the National Library of Medicine, the outbreak occurred in the year 1976. It struck southern Sudan and the northern part of the Democratic Republic of Congo and lasted for about four months, lasting from June to September, with a mortality rate of 53% and 88.1%, respectively. The two viruses that were later identified and held accountable for the first outbreak were Sudan ebolavirus and Zaire ebolavirus.

The growth and development of the Ebola virus vaccine market. The most important requirement is to handle the public health crisis caused by Ebola epidemics. The destructive effects of Ebola virus disease (EVD) on human health, as well as its potential for broad transmission, highlight the need for effective preventive measures.

The expansion and development of the Ebola virus vaccine market, establishing it as an essential component of global health security efforts. The combination of scientific, financial, regulatory, and geopolitical forces emphasizes the strong drivers propelling.

What are the Challenges Faced by the Ebola Virus Vaccine Market?

The current demand for Ebola vaccinations is mostly driven by outbreak response efforts. Widespread vaccination programs have yet to be undertaken due to variables such as the unexpected nature of outbreaks and the concentration of illnesses in low and middle income countries with limited medical resources.

High costs for developing and manufacturing vaccinations are costly operations. This can result in high vaccine pricing, thereby limiting affordability and accessibility in resource-constrained areas most vulnerable to epidemics.

Logistical challenges include distributing and storing vaccines in remote places with little infrastructure. Maintaining the requisite cold chain conditions for these vaccinations along the supply chain adds a new level of complication.

Stringent regulatory licensing for Ebola virus vaccines might severely impede market expansion. Regulatory requirements can slow the launch of new vaccinations and prevent new businesses from entering the market. Increasing approval time and expenses for vaccine development and commercialization may restrict market growth. Small enterprises with limited resources may struggle to comply with tight laws, which require comprehensive clinical trials, safety evaluations, and manufacturing requirements. Regulatory barriers might impede the commercialization and availability of Ebola virus vaccines, hindering market growth.

Category-Wise Acumens

How the Vesicular Stomatitis Virus Platform has emerged in Ebola Virus Vaccine Market?

In the Ebola virus vaccine the vesicular stomatitis virus (rVSV) platform has emerged as a dominant force and is rapidly expanding. The rVSV platform makes use of a genetically modified vesicular stomatitis virus, with the surface glycoprotein replaced by that of the Ebola virus. In clinical trials, this platform showed encouraging findings, including high effectiveness and the potential to induce powerful immune responses against Ebola virus infection.

Accine platforms, such as animal adenovirus type 3 (ChAd3) and adenovirus serotype 26 (Ad26), are also making progress in the sector. ChAd3 and Ad26 vaccines use adenovirus vectors to transmit genetic material encoding Ebola virus antigens, thereby inducing an immune response. These systems have shown efficacy and safety characteristics in clinical trials and are being investigated as potential replacements or complementing vaccines to the rVSV platform.

The Ebola virus vaccine market the rVSV platform presently leading. The ChAd3 and Ad26 platforms are also rapidly expanding and offer intriguing options in the search for effective Ebola virus vaccines. Continued research and development across many vaccine platforms is critical to addressing the complex challenges posed by Ebola virus infection and ensuring the availability of viable vaccines for future outbreaks.

How the Hospitals & Government Suppliers contain the supreme for several reasons for in Ebola Virus Vaccine Market?

The supreme for several reasons for Ebola Virus Vaccine the Hospitals and Government Suppliers this route is dominant for numerous reasons. Ebola outbreaks typically occur in areas with limited access to retail pharmacies. Because of the vaccines particular storage requirements (cold chain maintenance) hospitals and government entities have the facility and competence to handle them properly. Finally, during outbreaks, governments frequently coordinate vaccination programs, making them key distributors.

The Ebola vaccine market is likely to be limited position but online pharmacies are a fast-increasing part of the pharmaceutical industry. The aforementioned cold chain requirements, combined with the fact that Ebola vaccines are typically utilized during outbreaks (rather than for normal injections), make online pharmacies an unsuitable alternative.

How Vaccines and Healthcare Industries are increasing in North America by Ebola Virus Vaccine Market?

The increasing development of vaccines and pharmaceuticals in the healthcare industry, as well as the presence of leading pharmaceutical companies in North America, the market in this region is expected to rise significantly throughout the forecast period.

North America, especially the United States, has a booming pharmaceutical industry distinguished by cutting-edge R&D infrastructure, modern manufacturing capabilities and a favourable regulatory framework. The region is home to several renowned pharmaceutical corporations, including Pfizer, Johnson & Johnson, Merck & Co., and Moderna, among others, which are constantly investing in breakthrough medication discovery and development projects.

North America is expected to benefit from rapid expansion in the healthcare business. The region's premier pharmaceutical businesses, combined with ongoing investments in R&D and technical innovation, will propel healthcare forward and contribute to the region's status as a global pharmaceutical powerhouse.

How the Ebola virus vaccine market Present in Asia-Pacific?

The Ebola virus vaccine market in the Asia Pacific is a complex environment with many elements influencing its development and accessibility. Historically, the region has had less direct exposure to Ebola outbreaks than regions such as Africa, but concerns about the virus's potential spread and the need for preparedness have motivated increased focus on vaccine development and deployment.

The Asia Pacific area is distinguished by country-specific variations in healthcare infrastructure and resources. While some countries have advanced healthcare systems and research capacities, others confront severe challenges such as limited budget, inadequate infrastructure, and a healthcare manpower shortage. These obstacles can stymie vaccine research efforts and restrict access to immunizations in impoverished communities.

Asia Pacific offers chances for innovation and collaboration in the Ebola virus vaccination industry. As the region's healthcare infrastructure and research capacity improve, there is an opportunity for increased investment in vaccine development and distribution. Furthermore, addressing health inequities and ensuring fair access to vaccines will be critical to effectively managing possible Ebola outbreaks throughout Asia Pacific.

Competitive Landscape

The Ebola virus vaccine market industry companies use numerous tactics such as collaborations, acquisitions, mergers, and partnerships to establish a global presence and remain competitive. Please note that the company profile section includes both commercially available drugs and those in clinical development.

The Ebola Virus Vaccine Market study report will provide valuable insight with an emphasis on the global market. The major players in the market include:

Sarepta Therapeutics

Mapp Biopharmaceutical

Regeneron Pharmaceuticals, Inc.

GlaxoSmithKline plc.

Novavax, Inc.

GeoVax

Tekmira Pharmaceuticals

NewLink Genetics Corporation,

Bavarian Nordic

Merck & Co., Inc.

Johnson & Johnson.

Latest Developments

In October 2022, Merck & Co. will manufacture and give an investigational Sudan ebolavirus vaccine to a global non-profit organization's research program in Uganda, which is experiencing an outbreak.

In November 2021, the University of Oxford began phase one of its studies, evaluating the vaccine on human volunteers. In phase one of the studies, 26 participants aged 18 to 55 will get a single dose of the ChAdOx1 biEBOV Ebola vaccine at the university. They will subsequently be studied for six months, with the results expected in the second quarter of 2022.

In July 2020, Johnson & Johnson gained European Commission approval for an Ebola vaccine regimen for the prevention of Ebola Virus disease. The company's plan approval allows for collaboration with the World Health Organization (WHO) on vaccine pre-qualification, resulting in faster registration of its Ebola vaccine in African nations and a stronger market position.

1 INTRODUCTION OF GLOBAL EBOLA VIRUS VACCINE MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL EBOLA VIRUS VACCINE MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL EBOLA VIRUS VACCINE MARKET, BY VIRUS STRAIN

5.1 Overview
5.2 Recombinant Vesicular Stomatitis Virus
5.3 Chimpanzee Adeno Virus Type 3
5.4 Adeno Virus Serotype 26

6 GLOBAL EBOLA VIRUS VACCINE MARKET, BY DISTRIBUTION CHANNEL

6.1 Overview
6.2 Hospital & Retail Pharmacies
6.3 Online Pharmacies
6.4 Government suppliers
6.5 Others

7 GLOBAL EBOLA VIRUS VACCINE MARKET, BY END USER

7.1 Overview
7.2 Hospital
7.3 Homecare
7.4 Specialty Clinics
7.5 Ambulatory Surgical Centres
7.6 Others

8 GLOBAL EBOLA VIRUS VACCINE MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East & Africa

9 GLOBAL EBOLA VIRUS VACCINE MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Sarepta Therapeutics
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Mapp Biopharmaceutical
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Regeneron Pharmaceuticals, Inc.
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 GlaxoSmithKline plc.
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Novavax, Inc.
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 GeoVax
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Tekmira Pharmaceuticals
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 NewLink Genetics Corporation
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Bavarian Nordic
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Merck & Co., Inc.
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments

11 KEY DEVELOPMENTS

11.1 Product Launches/Developments
11.2 Mergers and Acquisitions
11.3 Business Expansions
11.4 Partnerships and Collaborations

12 Appendix

12.1 Related Research

에볼라 바이러스 백신 시장 : 바이러스 변종, 유통 채널, 최종 사용자, 지역별(2026-2032년)

Ebola Virus Vaccine Market By Virus Strain, Distribution Channel, End User, & Region for 2026-2032

에볼라 바이러스 백신 시장 평가(2026-2032년)

세계의 에볼라 바이러스 백신 시장이란?

에볼라 바이러스 백신 시장이 직면하는 과제란?

목차

제1장 세계의 에볼라 바이러스 백신 시장 도입

제2장 주요 요약

제3장 VERIFIED MARKET RESEARCH의 조사 방법

제4장 세계의 에볼라 바이러스 백신 시장 전망

제5장 세계의 에볼라 바이러스 백신 시장 : 바이러스 변종별

제6장 세계의 에볼라 바이러스 백신 시장 : 유통 채널별

제7장 세계의 에볼라 바이러스 백신 시장 : 최종 사용자별

제8장 세계의 에볼라 바이러스 백신 시장 : 지역별

제9장 세계의 에볼라 바이러스 백신 시장 경쟁 구도

제10장 기업 프로파일

제11장 주요 개발

제12장 부록

Ebola Virus Vaccine Market Valuation - 2026-2032